A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
Clinical trial NCT02132949 · COMPLETED
Trial details
- NCT number
- NCT02132949
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-14
- Primary completion
- 2016-03-03
- Enrollment
- 401
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.